Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2005;112:2887

This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
Related Collections
Right arrowRelated Articles

(Circulation. 2005;112:2887.)
© 2005 American Heart Association, Inc.

Issue Highlights


*    REVERSE REMODELING OF THE LEFT CARDIAC CHAMBERS AFTER CATHETER ABLATION AFTER 1 YEAR IN A SERIES OF PATIENTS WITH ISOLATED ATRIAL FIBRILLATION, by Reant et al.
up arrowTop
*REVERSE REMODELING OF THE...
down arrowMINERALOCORTICOID RECEPTOR...
down arrowABSORPTION, METABOLIZATION, AND...
down arrowClinician Update
down arrowImages in Cardiovascular...
down arrowCorrespondence
 
In patients with atrial fibrillation and no specific associated heart disease, there are identifiable abnormalities in structure and function, including left atrial dilation and abnormalities in diastolic ventricular function. An intriguing issue has been whether diastolic abnormalities are cause or consequence; are filling abnormalities related to the abnormal atrial dynamics, or might diastolic dysfunction (and consequent left atrial dilation) represent a driver of atrial fibrillation onset and maintenance? In this issue of Circulation, Reant and colleagues begin to dissect this issue by studying patients with isolated atrial fibrillation with echocardiography before and then 5 times during the year after radiofrequency ablation back to sinus rhythm. Left atrial size decreased, ventricular diastolic parameters improved, and ejection fraction increased. These data suggest that atrial fibrillation results in reversible structural and functional atrial and ventricular abnormalities in the absence of other specific pathologies. Diastolic abnormalities appear in large part a consequence rather than a cause of atrial fibrillation. See p 2896.


*    MINERALOCORTICOID RECEPTOR ANTAGONISM AMELIORATES LEFT VENTRICULAR DIASTOLIC DYSFUNCTION AND MYOCARDIAL FIBROSIS IN MILDLY SYMPTOMATIC PATIENTS WITH IDIOPATHIC DILATED CARDIOMYOPATHY: A PILOT STUDY, by Izawa et al.
up arrowTop
up arrowREVERSE REMODELING OF THE...
*MINERALOCORTICOID RECEPTOR...
down arrowABSORPTION, METABOLIZATION, AND...
down arrowClinician Update
down arrowImages in Cardiovascular...
down arrowCorrespondence
 
Landmark clinical trials have previously demonstrated the benefits of mineralocorticoid receptor antagonism in patients with symptomatic congestive heart failure. In fact, the Randomized Aldactone Evaluation Study (RALES) found that the addition of spironolactone to standard therapy reduced mortality by 30% in patients with NYHA class III or IV congestive heart failure. On the basis of these results, mineralocorticoid receptor antagonists have become widely accepted as part of the standard therapeutic regimen for patients with advanced symptoms due to congestive heart failure. It has been suggested that one mechanism by which mineralocorticoid receptor antagonists exert their beneficial effects is by decreasing myocardial fibrosis and, thereby, adverse ventricular remodeling; however, this effect has not been demonstrated directly. In this issue of Circulation, Izawa et al evaluate the effects of spironolactone on myocardial fibrosis regression in mildly symptomatic patients (NYHA class I or II) with dilated cardiomyopathy and correlate these findings with left ventricular diastolic function. See p 2940.


*    ABSORPTION, METABOLIZATION, AND ANTIPLATELET EFFECTS OF 300-, 600-, AND 900-MG LOADING DOSES OF CLOPIDOGREL: RESULTS OF THE ISAR-CHOICE (INTRACORONARY STENTING AND ANTITHROMBOTIC REGIMEN: CHOOSE BETWEEN 3 HIGH ORAL DOSES FOR IMMEDIATE CLOPIDOGREL EFFECT) TRIAL, by von Beckerath et al.
up arrowTop
up arrowREVERSE REMODELING OF THE...
up arrowMINERALOCORTICOID RECEPTOR...
*ABSORPTION, METABOLIZATION, AND...
down arrowClinician Update
down arrowImages in Cardiovascular...
down arrowCorrespondence
 
In patients undergoing percutaneous coronary intervention, the benefits of dual antiplatelet therapy with aspirin and clopidogrel after stent placement are well recognized; however, because of the variability in platelet inhibition observed among patients, investigators have questioned the optimal loading dose of this agent. Although the 300-mg loading dose of clopidogrel has been considered the standard regimen, recent studies have shown that a 600-mg loading dose provided additional, and more rapid, inhibition of platelet aggregation. Because of the observed benefit with an increased loading dose, investigators have now begun to study whether platelet inhibition may be augmented further by raising the loading dose to 900 mg. In this issue of Circulation, von Beckerath et al detail the results of a randomized trial of the antiplatelet effects and pharmacokinetics of 300-, 600-, and 900-mg loading doses of clopidogrel. See p 2946.

Visit http://www.circ.ahajournals.org:


*    Clinician Update
up arrowTop
up arrowREVERSE REMODELING OF THE...
up arrowMINERALOCORTICOID RECEPTOR...
up arrowABSORPTION, METABOLIZATION, AND...
*Clinician Update
down arrowImages in Cardiovascular...
down arrowCorrespondence
 
Homocysteine and Its Effects on In-Stent Restenosis. See p e307.


*    Images in Cardiovascular Medicine
up arrowTop
up arrowREVERSE REMODELING OF THE...
up arrowMINERALOCORTICOID RECEPTOR...
up arrowABSORPTION, METABOLIZATION, AND...
up arrowClinician Update
*Images in Cardiovascular...
down arrowCorrespondence
 
Medical Treatment of Varicose Veins. See p e312.

Acute Type I Aortic Dissection With Concomitant Pulmonary Artery Dissection. See p e313.

Detection of Active Coronary Arterial Vasculitis Using Magnetic Resonance Imaging in Kawasaki Disease. See p e315.



View larger version (57K):
[in this window]
[in a new window]
 


*    Correspondence
up arrowTop
up arrowREVERSE REMODELING OF THE...
up arrowMINERALOCORTICOID RECEPTOR...
up arrowABSORPTION, METABOLIZATION, AND...
up arrowClinician Update
up arrowImages in Cardiovascular...
*Correspondence
 
See p e317.


Related Articles:

Mineralocorticoid Receptor Antagonism Ameliorates Left Ventricular Diastolic Dysfunction and Myocardial Fibrosis in Mildly Symptomatic Patients With Idiopathic Dilated Cardiomyopathy: A Pilot Study
Hideo Izawa, Toyoaki Murohara, Kohzo Nagata, Satoshi Isobe, Hiroyuki Asano, Tetsuya Amano, Sahoko Ichihara, Tomoko Kato, Satoru Ohshima, Yosuke Murase, Shigeo Iino, Koji Obata, Akiko Noda, Kenji Okumura, and Mitsuhiro Yokota
Circulation 2005 112: 2940-2945. [Abstract] [Full Text]

Homocysteine and Its Effects on In-Stent Restenosis
Giuseppe De Luca, Harry Suryapranata, Giovanni Gregorio, Helmut Lange, and Massimo Chiariello
Circulation 2005 112: e307-e311. [Extract] [Full Text]

Medical Treatment of Varicose Veins
William Foster and Gerry Coghlan
Circulation 2005 112: e312. [Extract] [Full Text]

Acute Type I Aortic Dissection With Concomitant Pulmonary Artery Dissection
G. Khatchatourian and D. Vala
Circulation 2005 112: e313-e314. [Extract] [Full Text]

Detection of Active Coronary Arterial Vasculitis Using Magnetic Resonance Imaging in Kawasaki Disease
Colin J. McMahon, Jason T. Su, Michael D. Taylor, Rajesh Krishnamurthy, Raja Muthupillai, John P. Kovalchin, Taylor Chung, and G. Wesley Vick, III
Circulation 2005 112: e315-e316. [Extract] [Full Text]

Letter Regarding Article by Diwan et al, "Doppler Estimation of Left Ventricular Filling Pressures in Patients With Mitral Valve Disease" Response
Jin-Oh Choi, Sang-Chol Lee, Seung Woo Park, Abhinav Diwan, Marti McCulloch, Gerald M. Lawrie, Michael J. Reardon, and Sherif F. Nagueh
Circulation 2005 112: e317. [Extract] [Full Text]

Reverse Remodeling of the Left Cardiac Chambers After Catheter Ablation After 1 Year in a Series of Patients With Isolated Atrial Fibrillation
Patricia Reant, Stephane Lafitte, Pierre Jaïs, Karim Serri, Rukshen Weerasooriya, Meleze Hocini, Xavier Pillois, Jacques Clementy, Michel Haïssaguerre, and Raymond Roudaut
Circulation 2005 112: 2896-2903. [Abstract] [Full Text]

Absorption, Metabolization, and Antiplatelet Effects of 300-, 600-, and 900-mg Loading Doses of Clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial
Nicolas von Beckerath, Dirk Taubert, Gisela Pogatsa-Murray, Edgar Schömig, Adnan Kastrati, and Albert Schömig
Circulation 2005 112: 2946-2950. [Abstract] [Full Text]




This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
Related Collections
Right arrowRelated Articles